

1.	<p><b>Treatment &amp; Condition</b></p> <p>Bisphosphonates for treating osteoporosis (part review of TA160 and TA161)</p>
2.	<p><b>Associated appraisal body &amp; Summary of ruling</b></p> <p>NICE Technology Appraisal guidance (TA464) August 2017</p> <p>Oral bisphosphonates (alendronic acid, ibandronic acid and risedronate sodium) are recommended as options for treating osteoporosis in adults only if:</p> <ul style="list-style-type: none"> <li>• the person is eligible for risk assessment as defined in NICE's guideline on osteoporosis (recommendations 1.1 and 1.2) and the 10-year probability of osteoporotic fragility fracture is at least 1%.</li> </ul> <p>Intravenous bisphosphonates (ibandronic acid and zoledronic acid) are recommended as options for treating osteoporosis in adults only if:</p> <ul style="list-style-type: none"> <li>• the person is eligible for risk assessment as defined in NICE's guideline on osteoporosis (recommendations 1.1 and 1.2) and the 10-year probability of osteoporotic fragility fracture is at least 10% or</li> <li>• the 10-year probability of osteoporotic fragility fracture is at least 1% and</li> <li>• the person has difficulty taking oral bisphosphonates (alendronic acid, ibandronic acid or risedronate sodium) or these drugs are contraindicated or not tolerated.</li> </ul>
3.	<p><b>Number of people in Northern Ireland expected to take up service/therapy</b></p> <p>Implementation of this guidance offers an additional treatment option for treating active rheumatoid arthritis in adults.</p> <p>The NICE resource impact statement indicates that the guidance is not expected to have an impact on resources. This is because introduction of the technology is not expected to significantly change current practice.</p>
4.	<p><b>Patient Access Scheme Availability</b></p> <p>(Yes/<u>No</u>)</p>
5.	<p><b>Costs</b> (<i>before PAS if applicable</i>)</p>
5.1	<p><b>Drug cost per patient per annum (for new and prevalent cases)</b></p> <p>The resource impact template advises that practice is not anticipated to change substantially as a result of this guidance and the cost of treatment is low.</p> <p><u>Alendronic acid (generic)</u>          Cost per patient per annum ranges from £22.03 to £355.68 depending on the preparation used.</p>

	<p><u>Ibandronic acid (generic)</u> Cost per patient per annum ranges from £13.56 to £41.08 depending on the preparation used.</p> <p><u>Risedronate sodium (generic)</u> Cost per patient per annum ranges from £11.05 to £112.11 depending on the formulation used.</p> <p><u>Zoledronic acid (generic)</u> Cost per patient per annum = £7.36</p>
<b>5.2</b>	<p><b>Infrastructure costs Per annum</b></p> <p>Not anticipated.</p>
<b>6.</b>	<p><b>Expected implementation period</b></p> <p>There is no impediment to implementation of this guidance.</p>
<b>7.</b>	<p><b>Commissioning arrangements</b></p> <p>This regime will be formally commissioned by the HSCB/PHA via the Specialist Services Commissioning Team.</p>
<b>8.</b>	<p><b>Monitoring arrangements</b></p> <p>The HSC Board has robust arrangements in place for the monthly monitoring of all NICE Technology Appraisals and this regime will be included within the routinely provided return.</p>
<b>9.</b>	<p><b>DoH (NI) Legislative/Policy Caveats</b></p> <p>This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.</p>